192 related articles for article (PubMed ID: 18716616)
21. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
Ning YM; Maher VE
Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
[TBL] [Abstract][Full Text] [Related]
22. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
23. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
Bardia A; Baselga J
Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
[TBL] [Abstract][Full Text] [Related]
25. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
26. Imaging and oncologic drug development.
El-Deiry WS; Sigman CC; Kelloff GJ
J Clin Oncol; 2006 Jul; 24(20):3261-73. PubMed ID: 16829650
[TBL] [Abstract][Full Text] [Related]
27. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
28. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
[TBL] [Abstract][Full Text] [Related]
29. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
30. Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient.
Basch E; Geoghegan C; Coons SJ; Gnanasakthy A; Slagle AF; Papadopoulos EJ; Kluetz PG
JAMA Oncol; 2015 Jun; 1(3):375-9. PubMed ID: 26181187
[TBL] [Abstract][Full Text] [Related]
31. The FDA approves drugs for colorectal cancer, lung cancer.
FDA Consum; 2007; 41(1):5. PubMed ID: 17354284
[No Abstract] [Full Text] [Related]
32. Timing of first-in-child trials of FDA-approved oncology drugs.
Neel DV; Shulman DS; DuBois SG
Eur J Cancer; 2019 May; 112():49-56. PubMed ID: 30928805
[TBL] [Abstract][Full Text] [Related]
33. Conflicting signals on US accelerated approvals.
Fox JL
Nat Biotechnol; 2005 Sep; 23(9):1027-8. PubMed ID: 16151377
[No Abstract] [Full Text] [Related]
34. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
35. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
36. Japan works to shorten "drug lag," boost trials of new drugs.
Sinha G
J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
[No Abstract] [Full Text] [Related]
37. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
39. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
40. Challenges in drug development for muscle disease: a stakeholders' meeting.
Mendell JR; Csimma C; McDonald CM; Escolar DM; Janis S; Porter JD; Hesterlee SE; Howell RR
Muscle Nerve; 2007 Jan; 35(1):8-16. PubMed ID: 17068768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
